On March 19, 2024, the Board of Directors of Synlogic, Inc., following the recommendation of the Nominating and Governance Committee of the Board, appointed James Flynn effective March 19, 2024 (the Effective Date"), as a director to the Board to serve as a Class I Director with a term expiring at the Company's 2026 annual meeting of stockholders. Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in January 2021. Nerium Capital LLC is the General Partner of Nerium Partners LP, a healthcare focused investment partnership.

Mr. Flynn also currently serves as a Board Member for ARCA Biopharma, Inc., a biotechnology company dedicated to developing therapies for cardiovascular diseases, MEI Pharma, Inc., a clinical stage pharmaceutical company committed to developing novel and differentiated cancer therapies, and Ricebran Technologies, an innovative specialty ingredients company. From 2019 to 2020, Mr. Flynn was exploring business opportunities which ultimately led to the formation of Nerium Capital LLC. From 2017 to 2018, Mr. Flynn worked as a therapeutics analyst at Aptigon Capital (a Citadel Company), an investment firm.

Prior to that, from 2003 to 2017, Mr. Flynn served in various roles at Amici Capital, LLC, an investment firm, including healthcare portfolio manager (2008 to 2017). From 2002 to 2003, Mr. Flynn worked in the credit research/high yield group at Putnam Investments, an investment firm. Mr. Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachusetts Institute of Technology (MIT).

Mr. Flynn is a Chartered Financial Analyst (CFA) charterholder. On March 20, 2024, Mike Burgess, MB, CHB, Ph.D notified the Board of his decision to resign from the Board and the Audit Committee and the Science and Technology Committee, effective immediately. Dr. Burgess' decision to resign was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

On March 20, 2024, Lisa Kelly-Croswell notified the Board of her decision to resign from the Board and the Compensation Committee as well as the Nominating and Governance Committee, effective immediately. Ms. Kelly-Croswell's decision to resign was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices. On March 20, 2024, Patricia N. Hurter, Ph.D. notified the Board of her decision to resign from the Board and the Nominating and Governance Committee and the Science and Technology Committee, effective immediately.

Dr. Hurter's decision to resign was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.